Compare Stocks: SRPT, CTMX, EDIT, and APGE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.62	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
CTMX CytomX Therapeutics	$2.76	$3.37	$1.96 ▼ $8.21	$601.40M	2.14	3.97 million shs	9.60 million shs
EDIT Editas Medicine	$2.70	$2.90	$1.66 ▼ $4.54	$414.67M	2.09	2.98 million shs	17.03 million shs
SRPT Sarepta Therapeutics	$20.11	$18.62	$14.68 ▼ $25.32	$2.12B	0.27	3.17 million shs	6.29 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	+0.24%	+1.90%	+269.75%
CTMX CytomX Therapeutics	0.00%	-16.11%	-15.85%	-9.21%	+39.39%
EDIT Editas Medicine	0.00%	0.00%	-13.18%	-3.57%	-4.59%
SRPT Sarepta Therapeutics	0.00%	-1.66%	+7.03%	+13.94%	+15.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.07	$134.62	$35.39 ▼ $135.09	$8.40B	0.33	1.39 million shs	N/A
CTMX CytomX Therapeutics	$2.76	$3.37	$1.96 ▼ $8.21	$601.40M	2.14	3.97 million shs	9.60 million shs
EDIT Editas Medicine	$2.70	$2.90	$1.66 ▼ $4.54	$414.67M	2.09	2.98 million shs	17.03 million shs
SRPT Sarepta Therapeutics	$20.11	$18.62	$14.68 ▼ $25.32	$2.12B	0.27	3.17 million shs	6.29 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	0.00%	+0.24%	+1.90%	+269.75%
CTMX CytomX Therapeutics	0.00%	-16.11%	-15.85%	-9.21%	+39.39%
EDIT Editas Medicine	0.00%	0.00%	-13.18%	-3.57%	-4.59%
SRPT Sarepta Therapeutics	0.00%	-1.66%	+7.03%	+13.94%	+15.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.14% Downside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	331.16% Upside
EDIT Editas Medicine	2.60	Moderate Buy	$6.00	122.22% Upside
SRPT Sarepta Therapeutics	2.15	Hold	$25.69	27.73% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/9/2026	SRPT Sarepta Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
9/8/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/12/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
CTMX CytomX Therapeutics	$76.20M	7.89	N/A	N/A	$0.58 per share	4.76
EDIT Editas Medicine	$40.52M	10.23	N/A	N/A	$0.28 per share	9.64
SRPT Sarepta Therapeutics	$2.20B	0.97	N/A	N/A	$10.89 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	11.05	0.29	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest SRPT, CTMX, EDIT, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
CTMX CytomX Therapeutics	N/A	9.36	9.36
EDIT Editas Medicine	N/A	3.19	3.19
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
CTMX CytomX Therapeutics	3.80%
EDIT Editas Medicine	3.10%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
SRPT Sarepta Therapeutics	835	105.63 million	98.34 million	Optionable

SRPT, CTMX, EDIT, and APGE Headlines

Recent News About These Companies

Sarepta Therapeutics stock gains analyst support after mixed rating signals

September 20 at 6:45 PM | ad-hoc-news.deA

Sarepta Therapeutics stock holds near USD 19.76 after analyst reset

September 19 at 11:58 PM | ad-hoc-news.deA

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages

September 18 at 2:15 AM | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Brokerages

September 18 at 2:13 AM | marketbeat.com

Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

September 16, 2026 | marketbeat.com

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

September 15, 2026 | finance.yahoo.com

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

September 15, 2026 | marketbeat.com

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling

September 10, 2026 | news.alphastreet.comN

Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.6% - Here's Why

September 10, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4 Million Holdings in Sarepta Therapeutics, Inc. $SRPT

September 10, 2026 | marketbeat.com

Sarepta Therapeutics climbs 10%, rebounding from recent slide

September 9, 2026 | seekingalpha.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 10.3% - Here's Why

September 9, 2026 | marketbeat.com

Sarepta Therapeutics (SRPT) Plunges 10.3% to $20.18

September 8, 2026 | news.alphastreet.comN

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

September 8, 2026 | benzinga.com

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

September 8, 2026 | benzinga.com

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

September 8, 2026 | reuters.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Should You Sell?

September 8, 2026 | marketbeat.com

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

September 8, 2026 | finance.yahoo.com

Jupiter Topco LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

September 7, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Makes New $927,000 Investment in Sarepta Therapeutics, Inc. $SRPT

September 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRPT, CTMX, EDIT, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$135.07 0.00 (0.00%)

As of 09/4/2026

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

CytomX Therapeutics NASDAQ:CTMX

$2.76 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.78 +0.02 (+0.87%)

As of 07:35 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.70 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.75 +0.05 (+1.85%)

As of 07:37 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$20.11 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.16 +0.05 (+0.22%)

As of 07:25 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and APGE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and APGE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and APGE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools